Editas Medicine, Inc. Forecast, price target & analysts
Editas Medicine, Inc. Target price 2025 - Analyst rating & recommendation
Editas Medicine, Inc. Classifications & Recommendation:
Editas Medicine, Inc. Price Target
| Target Price | $3.44 |
| Price | $1.64 |
| Potential |
110.03%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Editas Medicine, Inc. 2026 .
The average Editas Medicine, Inc. target price is $3.44.
This is
110.03%
register free of charge
$5.00
204.88%
register free of charge
$1.00
39.02%
register free of charge
|
|
| A rating was issued by 16 analysts: 6 Analysts recommend Editas Medicine, Inc. to buy, 8 to hold and 2 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Editas Medicine, Inc. stock has an average upside potential 2026 of
110.03%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 32.31 | 15.69 |
| 58.64% | 51.45% | |
| EBITDA Margin | -721.48% | -974.88% |
| 245.52% | 35.12% | |
| Net Margin | -746.16% | -977.86% |
| 244.72% | 31.05% |
12 Analysts have issued a sales forecast Editas Medicine, Inc. 2025 . The average Editas Medicine, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Editas Medicine, Inc. EBITDA forecast 2025. The average Editas Medicine, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Editas Medicine, Inc. Analysts have issued a net profit forecast 2025. The average Editas Medicine, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.88 | -1.83 |
| 42.57% | 36.46% | |
| P/E | negative | |
| EV/Sales | negative |
5 Analysts have issued a Editas Medicine, Inc. forecast for earnings per share. The average Editas Medicine, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Editas Medicine, Inc....
Current Editas Medicine, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Baird |
Locked
➜
Locked
|
Locked | May 13 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 28 2025 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Dec 16 2024 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Dec 16 2024 |
| Barclays |
Locked
➜
Locked
|
Locked | Dec 13 2024 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Dec 13 2024 |
| Stifel |
Locked
➜
Locked
|
Locked | Dec 13 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Baird:
Locked
➜
Locked
|
May 13 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 28 2025 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Dec 16 2024 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Dec 16 2024 |
|
Locked
Barclays:
Locked
➜
Locked
|
Dec 13 2024 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Dec 13 2024 |
|
Locked
Stifel:
Locked
➜
Locked
|
Dec 13 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
